Novavax, Inc. (NASDAQ:NVAX) shares are trading lower Wednesday amid a pullback in the stock, which gained Tuesday after the FDA granted Emergency Use Authorization for the company’s updated protein-based COVID-19 vaccine for people 12 and older.
What To Know: Shares of Novavax surged Tuesday on news of FAD Emergency Use Authorization for its vaccine which is reportedly based on an older technology than the messenger RNA vaccines.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased